BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Blum KA, Gupta S, Tickoo SK, Chan TA, Russo P, Motzer RJ, Karam JA, Hakimi AA. Sarcomatoid renal cell carcinoma: biology, natural history and management. Nat Rev Urol 2020;17:659-78. [PMID: 33051619 DOI: 10.1038/s41585-020-00382-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Dibajnia P, Cardenas LM, Lalani AA. The emerging landscape of neo/adjuvant immunotherapy in renal cell carcinoma. Hum Vaccin Immunother 2023;19:2178217. [PMID: 36775257 DOI: 10.1080/21645515.2023.2178217] [Reference Citation Analysis]
2 Hahn AW, Kotecha RR, Viscuse PV, Pieretti AC, Wiele AJ, Jonasch E, Lee CH, Gao J, Zurita AJ, Shah AY, Campbell MT, Sharma P, Motzer RJ, Russo P, Wood CG, Tannir NM, Voss MH, Karam JA, Hakimi AA, Msaouel P. Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy. Eur Urol Focus 2023:S2405-4569(23)00048-2. [PMID: 36863962 DOI: 10.1016/j.euf.2023.02.008] [Reference Citation Analysis]
3 Dong A, Yang B, Bai Y, Zuo C. 68Ga-FAPI-04 PET/CT in a Small Sarcomatoid Renal Cell Carcinoma With Widespread Metastases. Clin Nucl Med 2023. [PMID: 36800242 DOI: 10.1097/RLU.0000000000004607] [Reference Citation Analysis]
4 Cheng M, Duzgol C, Kim TH, Ghafoor S, Becker AS, Causa Andrieu PI, Gangai N, Jiang H, Hakimi AA, Vargas HA, Woo S. Sarcomatoid renal cell carcinoma: MRI features and their association with survival. Cancer Imaging 2023;23:16. [PMID: 36793052 DOI: 10.1186/s40644-023-00535-0] [Reference Citation Analysis]
5 Boyle JJ, Pfail JL, Lichtbroun BJ, Singer EA. Adjuvant Therapy for Renal Cell Carcinoma: End Points, Outcomes, and Risk Assessments. JCO Precis Oncol 2023;7:e2200407. [PMID: 36724413 DOI: 10.1200/PO.22.00407] [Reference Citation Analysis]
6 Rustum YM, Reis R, Rustum TM. Druggable Biomarkers Altered in Clear Cell Renal Cell Carcinoma: Strategy for the Development of Mechanism-Based Combination Therapy. Int J Mol Sci 2023;24. [PMID: 36674417 DOI: 10.3390/ijms24020902] [Reference Citation Analysis]
7 Lyman GH, Msaouel P, Kuderer NM. Risk Model Development and Validation in Clinical Oncology: Lessons Learned. Cancer Invest 2023;41:1-11. [PMID: 36254812 DOI: 10.1080/07357907.2022.2137914] [Reference Citation Analysis]
8 Prakoso YA, Widyarini S, Faresy FC, Utomo YS. Clinicopathological study of sarcomatoid renal cell carcinoma in animals in East Java, Indonesia, from 2017 to 2022. Open Vet J 2023;13:64-73. [PMID: 36777435 DOI: 10.5455/OVJ.2023.v13.i1.7] [Reference Citation Analysis]
9 杨 桂. One Case Report of Sarcomatoid Renal Cell Carcinoma. ACM 2023;13:1906-1913. [DOI: 10.12677/acm.2023.132264] [Reference Citation Analysis]
10 Gupta S, Sukov WR, Vanderbilt CM, Shen W, Herrera-Hernandez L, Lohse CM, Thompson RH, Boorjian SA, Leibovich BC, Jimenez RE, Cheville JC. A contemporary guide to chromosomal copy number profiling in the diagnosis of renal cell carcinoma. Urol Oncol 2022;40:512-24. [PMID: 34092479 DOI: 10.1016/j.urolonc.2021.04.042] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
11 Wang N, Hakimi AA, Chen Y. XL-ing at Induction of Apoptosis in Kidney Cancer through Inhibition of BCL-XL. Clin Cancer Res 2022;28:4600-2. [PMID: 35984355 DOI: 10.1158/1078-0432.CCR-22-2104] [Reference Citation Analysis]
12 Parosanu A, Stanciu IM, Pirlog C, Orlov Slavu C, Cotan H, Iaciu C, Popa AM, Olaru M, Moldoveanu O, Catalin B, Nitipir C. Prognostic Models for Renal Cell Carcinoma in the Era of Immune Checkpoint Therapy. Cureus 2022. [DOI: 10.7759/cureus.30821] [Reference Citation Analysis]
13 Hahn AW, Lebenthal J, Genovese G, Sircar K, Tannir NM, Msaouel P. The significance of sarcomatoid and rhabdoid dedifferentiation in renal cell carcinoma. Cancer Treat Res Commun 2022;33:100640. [PMID: 36174377 DOI: 10.1016/j.ctarc.2022.100640] [Reference Citation Analysis]
14 xing Z, Chen Y, Cai G, Chen S. Clinical characteristic and survival analysis of distant metastatic sarcomatoid renal cell carcinoma: A study of 378 patients.. [DOI: 10.21203/rs.3.rs-1567322/v2] [Reference Citation Analysis]
15 Hino C, Nishino K, Pham B, Jeon WJ, Nguyen M, Cao H. Nivolumab plus ipilimumab induced endocrinopathy and acute interstitial nephritis in metastatic sarcomatoid renal-cell carcinoma: A case report and review of literature. Front Immunol 2022;13:993622. [DOI: 10.3389/fimmu.2022.993622] [Reference Citation Analysis]
16 Msaouel P, Lee J, Karam JA, Thall PF. A Causal Framework for Making Individualized Treatment Decisions in Oncology. Cancers (Basel) 2022;14:3923. [PMID: 36010916 DOI: 10.3390/cancers14163923] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Studentova H, Rusarova N, Ondruskova A, Zemankova A, Student V, Skanderova D, Melichar B. The Role of Cytoreductive Nephrectomy in Renal Cell Carcinoma with Sarcomatoid Histology: A Case Series and Review of the Literature. Current Oncology 2022;29:5475-5488. [DOI: 10.3390/curroncol29080433] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Vivekanandamoorthy N, Moghadam A, Hort A, Howle J. Malignant small bowel obstruction secondary to metastatic renal cell carcinoma with sarcomatoid transformation. Br J Hosp Med 2022;83:1-3. [DOI: 10.12968/hmed.2021.0626] [Reference Citation Analysis]
19 Tiako Meyo M, Chen J, Goldwasser F, Hirsch L, Huillard O. A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma. Ther Clin Risk Manag 2022;18:683-98. [PMID: 35837579 DOI: 10.2147/TCRM.S263832] [Reference Citation Analysis]
20 Patel HD, Man A, Koehne EL, Rac G, Aragao AP, Flanigan RC, Gorbonos A, Gupta GN, Woods ME, Picken MM, Quek ML. Percentage of sarcomatoid histology is associated with survival in renal cell carcinoma: Stratification and implications by clinical metastatic stage. Urologic Oncology: Seminars and Original Investigations 2022;40:347.e1-347.e8. [DOI: 10.1016/j.urolonc.2022.04.003] [Reference Citation Analysis]
21 Whaley RD, Cheng L. Clinicopathologic and Immunohistochemical Characterization of Sarcomatoid Chromophobe Renal Cell Carcinoma: An Analysis of 22 Cases. Am J Surg Pathol 2022. [PMID: 35687360 DOI: 10.1097/PAS.0000000000001926] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Warli SM, Andy A, Mariedina CT, Nasution R, Kadar DD. A Rare Case of Sarcomatoid Renal Cell Carcinoma in a Young Adult Patient. RRU 2022;Volume 14:241-245. [DOI: 10.2147/rru.s370975] [Reference Citation Analysis]
23 Al-juhaishi T, Deng X, Bandyopadhyay D, Paul A. The Role of Cytoreductive Nephrectomy and Targeted Therapy on Outcomes of Patients With Metastatic Sarcomatoid Renal Cell Carcinoma: A Population-Based Analysis. Cureus 2022. [DOI: 10.7759/cureus.25395] [Reference Citation Analysis]
24 Fuu T, Iijima K, Kusama Y, Otsuki T, Kato H. Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report. J Med Case Rep 2022;16:193. [PMID: 35581611 DOI: 10.1186/s13256-022-03426-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Lombardi P, Filetti M, Falcone R, Di Bidino R, Iacovelli R, Ciccarese C, Bria E, Tortora G, Scambia G, Daniele G. New first-line immunotherapy-based combinations for metastatic renal cell carcinoma: A systematic review and network meta-analysis. Cancer Treatment Reviews 2022;106:102377. [DOI: 10.1016/j.ctrv.2022.102377] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
26 Mar N, Uchio E, Kalebasty AR. Use of Immunotherapy in Clinical Management of Genitourinary Cancers – a Review. Cancer Treatment and Research Communications 2022. [DOI: 10.1016/j.ctarc.2022.100564] [Reference Citation Analysis]
27 Fontes-sousa M, Calvo E. First-line immune checkpoint inhibitors in advanced or metastatic renal cell carcinoma with sarcomatoid features. Cancer Treatment Reviews 2022. [DOI: 10.1016/j.ctrv.2022.102374] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
28 Bhat P, Hwang M, Jahedi A, Sircar K, Kannan K. Spatial Point Process Model Predicts Survival in Clear Cell Renal Cell Carcinoma.. [DOI: 10.1101/2022.02.16.22271019] [Reference Citation Analysis]
29 Chen Q, Fu Q, Pu L, Liu X, Liu Y. Effects of HMGA2 gene silencing on cell cycle and apoptosis in the metastatic renal carcinoma cell line ACHN. J Int Med Res 2022;50:3000605221075511. [PMID: 35118889 DOI: 10.1177/03000605221075511] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Brown JR, Calaway A, Castle E, Garcia J, Barata PC. Systematic Review of Treatment of Metastatic Non-Clear Cell Renal Cell Carcinoma. KCA 2022. [DOI: 10.3233/kca-210005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 An J, Packiam VT, Chennamadhavuni A, Richards J, Jain J, Mott SL, Garje R. Patient Characteristics and Survival Outcomes of Non-Metastatic, Non-Clear Cell Renal Cell Carcinoma. Front Oncol 2021;11:786307. [PMID: 35083144 DOI: 10.3389/fonc.2021.786307] [Reference Citation Analysis]
32 Mattila KE, Vainio P, Jaakkola PM. Prognostic Factors for Localized Clear Cell Renal Cell Carcinoma and Their Application in Adjuvant Therapy. Cancers (Basel) 2022;14:239. [PMID: 35008402 DOI: 10.3390/cancers14010239] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
33 Candelario N, Geiger C, Flaig T. Sarcomatoid Renal Cell Carcinoma: The Present and Future of Treatment Paradigms. KCA 2021;5:167-79. [DOI: 10.3233/kca-210126] [Reference Citation Analysis]
34 Buti S, Bersanelli M, Mazzaschi G, Cattrini C, Brunelli M, Maio MD. Can we identify a preferred first-line strategy for sarcomatoid renal cell carcinoma? A network meta-analysis. Immunotherapy 2021. [PMID: 34806404 DOI: 10.2217/imt-2021-0157] [Reference Citation Analysis]
35 Anker J, Miller J, Taylor N, Kyprianou N, Tsao CK. From Bench to Bedside: How the Tumor Microenvironment Is Impacting the Future of Immunotherapy for Renal Cell Carcinoma. Cells 2021;10:3231. [PMID: 34831452 DOI: 10.3390/cells10113231] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
36 Jang A, Adler DM, Rauterkus GP, Bilen MA, Barata PC. Immunotherapies in Genitourinary Oncology: Where Are We Now? Where Are We Going? Cancers (Basel) 2021;13:5065. [PMID: 34680214 DOI: 10.3390/cancers13205065] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
37 Agaimy A, Hartmann A, Trpkov K, Hes O. Undifferentiated and dedifferentiated urological carcinomas: lessons learned from the recent developments. Semin Diagn Pathol 2021;38:152-62. [PMID: 34579992 DOI: 10.1053/j.semdp.2021.09.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Mar N, Kaakour D, Rezazadeh Kalebasty A. Renal Cell Carcinoma-Lessons in Diversity, Breakthroughs, and Challenges. JCO Oncol Pract 2021;:OP2100446. [PMID: 34550754 DOI: 10.1200/OP.21.00446] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
39 Santoni M, Massari F, Grande E, Procopio G, Matrana MR, Rizzo M, De Giorgi U, Basso U, Milella M, Iacovelli R, Aurilio G, Incorvaia L, Buti S, Caffo O, Fornarini G, Carrozza F, Mollica V, Rizzo A, Farag F, Molina-Cerrillo J, Battelli N. Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study. Target Oncol 2021. [PMID: 34338966 DOI: 10.1007/s11523-021-00828-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
40 Tanguay S, Abel EJ, Albigès L, Choueiri T, Bex A, Capitanio U, Tran M, Volpe A, Black PC. B2B: Kidney Cancer Summary. Proceedings from the SIU B2B Uro-Oncology: GU Cancers Triad Virtual Meeting May 21–22, 2021 2021;2:S19-S28. [DOI: 10.48083/scpm5983] [Reference Citation Analysis]
41 Geynisman DM, Maranchie JK, Ball MW, Bratslavsky G, Singer EA. A 25 year perspective on the evolution and advances in an understanding of the biology, evaluation and treatment of kidney cancer. Urol Oncol 2021;39:548-60. [PMID: 34092483 DOI: 10.1016/j.urolonc.2021.04.038] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
42 Sobottka B, Lorch A, Silina K, van den Broek M, Moch H. Renal cell carcinoma pathology in 2021: 'new need for renal cancer immune profiling'. Curr Opin Urol 2021;31:228-35. [PMID: 33742986 DOI: 10.1097/MOU.0000000000000864] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
43 Dumond A, Montemagno C, Vial V, Grépin R, Pagès G. Anti-Vascular Endothelial Growth Factor C Antibodies Efficiently Inhibit the Growth of Experimental Clear Cell Renal Cell Carcinomas. Cells 2021;10:1222. [PMID: 34067671 DOI: 10.3390/cells10051222] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]